667 related articles for article (PubMed ID: 37964320)
21. Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.
Weng X; He Y; Visvabharathy L; Liao CM; Tan X; Balakumar A; Wang CR
J Hepatol; 2017 Oct; 67(4):791-800. PubMed ID: 28596110
[TBL] [Abstract][Full Text] [Related]
22. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
23. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
24. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine.
Kishida N; Matsuda S; Itano O; Shinoda M; Kitago M; Yagi H; Abe Y; Hibi T; Masugi Y; Aiura K; Sakamoto M; Kitagawa Y
BMC Gastroenterol; 2016 Jun; 16(1):61. PubMed ID: 27296438
[TBL] [Abstract][Full Text] [Related]
26. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
27. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
28. Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations.
Heinrichs D; Brandt EF; Fischer P; Köhncke J; Wirtz TH; Guldiken N; Djudjaj S; Boor P; Kroy D; Weiskirchen R; Bucala R; Wasmuth HE; Strnad P; Trautwein C; Bernhagen J; Berres ML
Cells; 2021 Jan; 10(2):. PubMed ID: 33525493
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.
Chiba T; Suzuki S; Sato Y; Itoh T; Umegaki K
PLoS One; 2016; 11(10):e0164191. PubMed ID: 27723801
[TBL] [Abstract][Full Text] [Related]
30. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance.
Satoh M; Andoh Y; Clingan CS; Ogura H; Fujii S; Eshima K; Nakayama T; Taniguchi M; Hirata N; Ishimori N; Tsutsui H; Onoé K; Iwabuchi K
PLoS One; 2012; 7(2):e30568. PubMed ID: 22383967
[TBL] [Abstract][Full Text] [Related]
31.
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2022; 13():1047570. PubMed ID: 36531991
[TBL] [Abstract][Full Text] [Related]
32. Gender differences in diet-induced steatotic disease in Cyp2b-null mice.
Heintz MM; McRee R; Kumar R; Baldwin WS
PLoS One; 2020; 15(3):e0229896. PubMed ID: 32155178
[TBL] [Abstract][Full Text] [Related]
33. NKT cell modulates NAFLD potentiation of metabolic oxidative stress-induced mesangial cell activation and proximal tubular toxicity.
Alhasson F; Dattaroy D; Das S; Chandrashekaran V; Seth RK; Schnellmann RG; Chatterjee S
Am J Physiol Renal Physiol; 2016 Jan; 310(1):F85-F101. PubMed ID: 26447219
[TBL] [Abstract][Full Text] [Related]
34. Hepatic Natural Killer T-cell and CD8+ T-cell Signatures in Mice with Nonalcoholic Steatohepatitis.
Bhattacharjee J; Kirby M; Softic S; Miles L; Salazar-Gonzalez RM; Shivakumar P; Kohli R
Hepatol Commun; 2017 Jun; 1(4):299-310. PubMed ID: 29152605
[TBL] [Abstract][Full Text] [Related]
35. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis.
Wehr A; Baeck C; Heymann F; Niemietz PM; Hammerich L; Martin C; Zimmermann HW; Pack O; Gassler N; Hittatiya K; Ludwig A; Luedde T; Trautwein C; Tacke F
J Immunol; 2013 May; 190(10):5226-36. PubMed ID: 23596313
[TBL] [Abstract][Full Text] [Related]
36. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
[TBL] [Abstract][Full Text] [Related]
37. β
Drescher HK; Schippers A; Clahsen T; Sahin H; Noels H; Hornef M; Wagner N; Trautwein C; Streetz KL; Kroy DC
J Hepatol; 2017 Jun; 66(6):1251-1264. PubMed ID: 28192190
[TBL] [Abstract][Full Text] [Related]
38. CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis.
Lei Z; Yu J; Wu Y; Shen J; Lin S; Xue W; Mao C; Tang R; Sun H; Qi X; Wang X; Xu L; Wei C; Wang X; Chen H; Hao P; Yin W; Zhu J; Li Y; Wu Y; Liu S; Liang H; Chen X; Su C; Zhou S
J Hepatol; 2024 Feb; 80(2):194-208. PubMed ID: 38438948
[TBL] [Abstract][Full Text] [Related]
39. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
40. Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu.
Gabbia D; Sayaf K; Zanotto I; Colognesi M; Frion-Herrera Y; Carrara M; Russo FP; De Martin S
Eur J Pharmacol; 2024 Apr; 969():176453. PubMed ID: 38408597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
